No products in the cart
N-Acetyl Selank (10mg)
N-Acetyl Selank peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is the N-Acetyl Selank peptide?
N-Acetyl Selank is an acetylated form of the Selank peptide. The acetylation of the peptide into N-Acetyl Selank appears to improve its stability. Selank is a synthetic analogue of the natural human tetrapeptide Tuftsin. Tuftsin is an immunomodulatory peptide, and N-Acetyl Selank appears to possess many of its effects. In addition, N-acetyl Selank also appears to exhibit effects on neurotransmitters, brain signaling, and neuroplasticity.
Molecular Formula: C35H59N11O10
Molecular Weight: 793.91 g/mol
N-Acetyl Selank as a Nootropic
N-Acetyl Selank may have similar effects as Selank, but with the potential for increased efficacy and stability. In research studies with rat subjects, scientists suggest that the peptide activates the serotonin metabolism in the tested animals’ brains. As a result, administering Selank appeared to enhance memory storage processes compared to a placebo. Researchers have also investigated the effect of Selank on humans when given alongside a control medication to individuals with anxiety-phobic, hypochondriac, and somatoform disorders. Compared to the control medication alone, the combination of Selank and the medication appeared to have increased efficacy and reduced known side effects of the medication. The patients on combination therapy appeared to experience less attention and memory impairment, asthenia, and sedation.
N-Acetyl Selank as a Anxiolytic
The anxiolytic effects of Selank have been studied experimentally. In laboratory research, Selank was posited to increase the levels of calming neurotransmitters such as serotonin in the brains of rats. Serotonin is a primary target of most anxiolytics, and blocking its reuptake is a common mechanism of action for these medications. Additional clinical research in patients with a generalized anxiety disorder (GAD) and neurasthenia compared the effect of Selank to that of a control medication in reducing symptoms and improving quality of life. The researchers reported that the anxiolytic effects of both the medication and the peptide were similar, but Selank appeared to have additional antiasthenic and psychostimulant effects. They noted that “patients with GAD and neurasthenia had the decreased level of tau(1/2) leu-enkephalin, which was correlated with disease duration, severity of symptoms related to anxiety and asthenia and autonomic disorders”. Selank has an inhibitory effect on enkephalin-degrading enzymes, which is likely the primary mechanism of its supposed anxiolytic activity.
N-Acetyl Selank and Neuroplasticity
N-Acetyl Selank may upregulate the brain-derived neurotrophic factor (BDNF) levels in the central nervous system. Animal studies show that the administration of Selank may increase BDNF levels in the hippocampus. BDNF is a growth factor in the brain that supports neurons’ growth and adaptation. According to scientists, BDNF may also induce remodeling in the nerve tissue and the formation of new connections. BDNF may also stimulate neurogenesis, the formation of new neurons in parts of the adult brain that retain stem cells. With this research, it is suggested that Selank may protect the brain and stimulate neural plasticity.
- Semenova TP, Kozlovskiĭ II, Zakharova NM, Kozlovskaia MM. [Experimental optimization of learning and memory processes by selank]. Eksp Klin Farmakol. 2010 Aug;73(8):2-5. Russian. PMID: 20919548.
- Medvedev VE, Tereshchenko ON, Kost NV, Ter-Israelyan AY, Gushanskaya EV, Chobanu IK, Sokolov OY, Myasoedov NF. [Optimization of the treatment of anxiety disorders with selank]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. Russian. doi: 10.17116/jnevro20151156133-40. PMID: 26356395.
- Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. Russian. PMID: 25176261.
- Semenova TP, kozlovskiĭ II, Zakharova NM, Kozlovskaia MM. [Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA]. Eksp Klin Farmakol. 2009 Jul-Aug;72(4):6-8. Russian. PMID: 19803361.
- Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. Russian. PMID: 18454096.
- Zozulya AA, Kost NV, Yu Sokolov O, Gabaeva MV, Grivennikov IA, Andreeva LN, Zolotarev YA, Ivanov SV, Andryushchenko AV, Myasoedov NF, Smulevich AB. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001 Apr;131(4):315-7. doi: 10.1023/a:1017979514274. PMID: 11550013.
- Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008 Jul-Aug;421:241-3. doi: 10.1134/s0012496608040066. PMID: 18841804.
- Deister C, Schmidt CE. Optimizing neurotrophic factor combinations for neurite outgrowth. J Neural Eng. 2006 Jun;3(2):172-9. doi: 10.1088/1741-2560/3/2/011. Epub 2006 May 16. PMID: 16705273.
- Lu B, Figurov A. Role of neurotrophins in synapse development and plasticity. Rev Neurosci. 1997 Jan-Mar;8(1):1-12. doi: 10.1515/revneuro.19188.8.131.52. PMID: 9402641.
- Zigova T, Pencea V, Wiegand SJ, Luskin MB. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci. 1998 Jul;11(4):234-45. doi: 10.1006/mcne.1998.0684. PMID: 9675054.
There are no reviews yet.